Halma PLC has acquired Rovers Medical Devices B.V., a company based in the Netherlands that designs and manufactures sample collection devices used in the prevention and diagnostics of cervical cancer. The initial consideration for the acquisition is €85m, with an additional consideration of up to €6m based on Rovers' performance. Rovers' unaudited revenue for the 12 months to 31 December 2023 was €12.0m, with Return on Sales more than double Halma's target range of 18-22%. Rovers will operate as a standalone company within Halma's Healthcare sector, led by its current management team.
The acquisition is expected to broaden the range of markets served in women's health and strengthen Halma's Healthcare sector's position in cancer diagnosis products. Halma's Group Chief Executive, Marc Ronchetti, expressed excitement about the opportunities to increase Rovers' positive impact on public health, driven by increasing global cervical screening rates. Rovers' CEO, Roel Leenders, highlighted the alignment of Rovers' mission with Halma's in improving the quality of care for patients and the potential for growth and collaboration within the Halma group.
Halma is a global group of life-saving technology companies, operating in the Health, Environment, and Safety markets. It employs over 8,000 people in more than 20 countries and is listed on the London Stock Exchange. The company has been named as one of Britain's Most Admired Companies for the past five years.
For further information, please visit www.halma.com.